Skip to content
← Holders

Logos Global Management LP

What Logos Global Management LP reported holding on Form 13F for the quarter ended Sep 30, 2026.

CIK 1792126 · Filed Nov 16, 2026

Positions
72
Reported value
$1.9B
Opened
29
Closed
25
Other managers included
0

Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR

Quarters on file

  1. Sep 30, 2025$1.1B
    59 positions
  2. Dec 31, 2025$1.7B
    69 positions
  3. Mar 31, 2026$2B
    66 positions
  4. Jun 30, 2026$2.3B
    68 positions
  5. Sep 30, 2026$1.9B
    72 positions
SecuritySharesChangeValueOf portfolio
PRAXPraxis Precision Medicines, Inc.
425K+63.5%$123.8M6.7%
RVMDRevolution Medicines, Inc.
600K−14.3%$123.2M6.6%
IDYAIDEAYA Biosciences, Inc.
2.9M−5.0%$109.5M5.9%
ERASErasca, Inc.
5.9M−51.4%$86.5M4.7%
ABVXAbivax S.A.
870K−15.0%$86.1M4.6%
CGONCG Oncology, Inc.
975K−2.5%$69.1M3.7%
IRONDisc Medicine, Inc.
1M+16.0%$66.4M3.6%
BNTXBioNTech SE
650K−36.0%$63.9M3.4%
TNGXTango Therapeutics, Inc.
2.2M−24.6%$53.6M2.9%
MDGLMadrigal Pharmaceuticals, Inc.
100KNew$50.4M2.7%
ELVNEnliven Therapeutics, Inc.
1.1M+132.3%$49.5M2.7%
DYNDyne Therapeutics, Inc.
3M+17.6%$48.3M2.6%
OCULOcular Therapeutix, Inc
6M+13.2%$46M2.5%
DNTHDianthus Therapeutics, Inc.
500K−37.5%$44M2.4%
AVBPArriVent BioPharma, Inc.
1.4M+35.0%$40.9M2.2%
COGTCogent Biosciences, Inc.
1.3M+38.9%$40M2.2%
ERASErasca, Inc.Call option
2.5MNew$36.7M2%
NBIXNeurocrine Biosciences Inc
250KNew$35.5M1.9%
BLTEBelite Bio, Inc
200K−20.0%$34M1.8%
AXSMAxsome Therapeutics, Inc.
175KNew$32.3M1.7%
GPCRStructure Therapeutics Inc.
1M+100.0%$31.3M1.7%
OLMAOlema Oncology, Inc.
3.2M±0%$27.7M1.5%
ACHVAchieve Life Sciences, Inc.
3.2M−41.0%$25.9M1.4%
MAZEMaze Therapeutics, Inc.
935K−51.7%$25.4M1.4%
PBLSParabilis Medicines, Inc.
750K+42.9%$24.2M1.3%
APMDApnimed, Inc.
1.1MNew$24.1M1.3%
YARWYarrow Bioscience, Inc.
1MNew$23.1M1.2%
AVTXAvalo Therapeutics, Inc.Call option
1.5MNew$23M1.2%
TRVITrevi Therapeutics, Inc.
1.4M−23.1%$20.7M1.1%
MANEVeradermics, Inc
170K−5.6%$20.6M1.1%
REPLReplimune Group, Inc.Call option
1.5MNew$19.9M1.1%
VERAVera Therapeutics, Inc.
600K−72.7%$19.4M1%
DSGNDesign Therapeutics, Inc.Call option
1.5MNew$18.9M1%
SRPTSarepta Therapeutics, Inc.
1MNew$18.2M1%
SRPTSarepta Therapeutics, Inc.Call option
1MNew$18.2M1%
MLTXMoonLake Immunotherapeutics
1.5M−43.9%$17.6M0.9%
SMMTSummit Therapeutics Inc.Call option
1MNew$16.9M0.9%
IMCRImmunocore Holdings plc
500K−16.7%$15.1M0.8%
BHVNBiohaven Ltd.
1.1MNew$14.7M0.8%
CRSPCRISPR Therapeutics AG
250K−16.7%$13.8M0.7%
BHVNBiohaven Ltd.Call option
1MNew$13.4M0.7%
DFTXDefinium Therapeutics, Inc.
350K+337.5%$13.3M0.7%
RCUSArcus Biosciences, Inc.Call option
500KNew$12.9M0.7%
ENTXEntera Bio Ltd.
4.4MNew$12.8M0.7%
DSGNDesign Therapeutics, Inc.
1M−66.7%$12.6M0.7%
CMPSCOMPASS Pathways plcCall option
1MNew$12.4M0.7%
CBIOCrescent Biopharma, Inc.
850K−55.3%$12.4M0.7%
ETRAElectra Therapeutics, Inc.
1MNew$11.3M0.6%
NERVMinerva Neurosciences, Inc.
3.3M±0%$11M0.6%
LBRXLB Pharmaceuticals Inc
250K−57.3%$9.6M0.5%
ACHVAchieve Life Sciences, Inc.Call option
1MNew$8.1M0.4%
ALMSAlumis Inc.Call option
1MNew$7.4M0.4%
IVAInventiva S.A.Call option
2MNew$7.4M0.4%
EYPTEyePoint, Inc.Call option
2MNew$6.5M0.4%
VKTXViking Therapeutics, Inc.
200KNew$6.5M0.4%
EDITEditas Medicine, Inc.
2.2M±0%$5.7M0.3%
TNXPTonix Pharmaceuticals Holding Corp.
550KNew$5.4M0.3%
IRDOpus Genetics, Inc.
1MNew$4.8M0.3%
VOGXVogenx, Inc.
205KNew$4.7M0.3%
IMVTImmunovant, Inc.
85K−87.2%$2.9M0.2%
JBIOJade Biosciences, Inc.
200K−82.2%$2.8M0.2%
OKUROnKure Therapeutics, Inc.
963.9K±0%$2.6M0.1%
TCGXTCGX Acquisition Corp.
200KNew$2.5M0.1%
UNCYUnicycive Therapeutics, Inc.
473.6K±0%$2.2M0.1%
PTNPalatin Technologies Inc
129.3K−0.6%$1.1M0.1%
JATTJATT II Acquisition Corp.
100K±0%$1.1M0.1%
JTTTJATT III Acquisition Corp
100KNew$1.1M0.1%
RACCResearch Alliance Corp III
100K±0%$1.1M0.1%
SEPNSepterna, Inc.
23.5K±0%$921.4K0.1%
AMANAmanat Acquisition Corp.
50K±0%$534K0.1%
LGVNLongeveron Inc.
192.3KNew$517.3K0.1%
GUTSFractyl Health, Inc.
505K−49.5%$274.9K0.1%